AU2989799A - Ribozymes capable of inhibiting the expression of the ccr5 receptor - Google Patents
Ribozymes capable of inhibiting the expression of the ccr5 receptor Download PDFInfo
- Publication number
- AU2989799A AU2989799A AU29897/99A AU2989799A AU2989799A AU 2989799 A AU2989799 A AU 2989799A AU 29897/99 A AU29897/99 A AU 29897/99A AU 2989799 A AU2989799 A AU 2989799A AU 2989799 A AU2989799 A AU 2989799A
- Authority
- AU
- Australia
- Prior art keywords
- ribozyme
- ccr5
- cells
- vector
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108091092562 ribozyme Proteins 0.000 title claims abstract description 105
- 108090000994 Catalytic RNA Proteins 0.000 title claims abstract description 103
- 102000053642 Catalytic RNA Human genes 0.000 title claims abstract description 103
- 102000004274 CCR5 Receptors Human genes 0.000 title claims abstract description 7
- 108010017088 CCR5 Receptors Proteins 0.000 title claims abstract description 7
- 230000014509 gene expression Effects 0.000 title claims description 18
- 230000002401 inhibitory effect Effects 0.000 title description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 32
- 238000000034 method Methods 0.000 claims abstract description 21
- 230000002222 downregulating effect Effects 0.000 claims abstract description 5
- 210000004027 cell Anatomy 0.000 claims description 44
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims description 34
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims description 34
- 239000013598 vector Substances 0.000 claims description 19
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 239000002502 liposome Substances 0.000 claims description 8
- 108020004999 messenger RNA Proteins 0.000 claims description 8
- 208000031886 HIV Infections Diseases 0.000 claims description 6
- 239000013604 expression vector Substances 0.000 claims description 6
- 230000003394 haemopoietic effect Effects 0.000 claims description 6
- 239000002243 precursor Substances 0.000 claims description 6
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 5
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 5
- 230000003197 catalytic effect Effects 0.000 claims description 5
- 210000004962 mammalian cell Anatomy 0.000 claims description 5
- 208000037357 HIV infectious disease Diseases 0.000 claims description 4
- 108091036078 conserved sequence Proteins 0.000 claims description 4
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 4
- 241000713869 Moloney murine leukemia virus Species 0.000 claims description 3
- 108091028664 Ribonucleotide Proteins 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000002336 ribonucleotide Substances 0.000 claims description 3
- 125000002652 ribonucleotide group Chemical group 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- 239000005547 deoxyribonucleotide Substances 0.000 claims description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims description 2
- 230000001177 retroviral effect Effects 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims 4
- 230000002463 transducing effect Effects 0.000 claims 3
- 238000011321 prophylaxis Methods 0.000 claims 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract description 6
- 238000003776 cleavage reaction Methods 0.000 description 19
- 239000002773 nucleotide Substances 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 10
- 125000003729 nucleotide group Chemical group 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 230000007017 scission Effects 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- 230000000692 anti-sense effect Effects 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 108090001102 Hammerhead ribozyme Proteins 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 102000009572 RNA Polymerase II Human genes 0.000 description 2
- 108010009460 RNA Polymerase II Proteins 0.000 description 2
- 102000014450 RNA Polymerase III Human genes 0.000 description 2
- 108010078067 RNA Polymerase III Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 101150072531 10 gene Proteins 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000001902 CC Chemokines Human genes 0.000 description 1
- 108010040471 CC Chemokines Proteins 0.000 description 1
- 101150017501 CCR5 gene Proteins 0.000 description 1
- 102000001327 Chemokine CCL5 Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241000701832 Enterobacteria phage T3 Species 0.000 description 1
- 241000701867 Enterobacteria phage T7 Species 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 230000007022 RNA scission Effects 0.000 description 1
- 241000251131 Sphyrna Species 0.000 description 1
- 101150018082 U6 gene Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- CAAULPUQFIIOTL-UHFFFAOYSA-N methyl dihydrogen phosphate Chemical compound COP(O)(O)=O CAAULPUQFIIOTL-UHFFFAOYSA-N 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000010648 susceptibility to HIV infection Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/121—Hammerhead
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Tropical Medicine & Parasitology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/038,741 US6100087A (en) | 1998-03-11 | 1998-03-11 | Ribozymes targeted to human CCR5 mRNA |
| US09038741 | 1998-03-11 | ||
| PCT/US1999/005011 WO1999046372A2 (en) | 1998-03-11 | 1999-03-05 | Ribozymes capable of inhibiting the expression of the ccr5 receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2989799A true AU2989799A (en) | 1999-09-27 |
Family
ID=21901629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU29897/99A Abandoned AU2989799A (en) | 1998-03-11 | 1999-03-05 | Ribozymes capable of inhibiting the expression of the ccr5 receptor |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6100087A (ja) |
| EP (1) | EP1062330B1 (ja) |
| JP (1) | JP4330797B2 (ja) |
| AT (1) | ATE342969T1 (ja) |
| AU (1) | AU2989799A (ja) |
| CA (1) | CA2323109A1 (ja) |
| DE (1) | DE69933653T2 (ja) |
| WO (1) | WO1999046372A2 (ja) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6743594B1 (en) | 1995-06-06 | 2004-06-01 | Human Genome Sciences, Inc. | Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5) |
| US6025154A (en) | 1995-06-06 | 2000-02-15 | Human Genome Sciences, Inc. | Polynucleotides encoding human G-protein chemokine receptor HDGNR10 |
| DE69637890D1 (de) | 1995-06-07 | 2009-05-14 | Progenics Pharm Inc | Monoklonaler antikörper für die inhibierung von hiv-1-hüllgykoprotein-vermittelte membranfusion |
| US7118859B2 (en) * | 1996-01-17 | 2006-10-10 | Progenics Pharmaceuticals, Inc. | Methods for inhibiting HIV-1 infection |
| US7858298B1 (en) | 1996-04-01 | 2010-12-28 | Progenics Pharmaceuticals Inc. | Methods of inhibiting human immunodeficiency virus type 1 (HIV-1) infection through the administration of CCR5 chemokine receptor antagonists |
| US6344545B1 (en) * | 1996-06-14 | 2002-02-05 | Progenics Pharmaceuticals, Inc. | Method for preventing HIV-1 infection of CD4+ cells |
| US20040086528A1 (en) * | 1996-06-14 | 2004-05-06 | Progenics Pharmaceuticals, Inc. | Uses of a chemokine receptor for inhibiting HIV-1 infection |
| US20080015348A1 (en) * | 1998-12-16 | 2008-01-17 | Progenics Pharmaceuticals, Inc. | Nucleic acids encoding polypeptides of anti-CCR5 antibodies |
| US20040228869A1 (en) * | 1998-12-16 | 2004-11-18 | Progenics Pharmaceuticals, Inc. | Synergistic inhibition of HIV-1 fusion and attachment, compositions and antibodies thereto |
| US6534261B1 (en) * | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| DE19956568A1 (de) * | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| JP2003500061A (ja) * | 1999-05-21 | 2003-01-07 | オックスフォード バイオメディカ（ユーケイ）リミテッド | 改善されたレトロウイルスの産生 |
| US7829693B2 (en) * | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| US7138119B2 (en) * | 2000-09-15 | 2006-11-21 | Progenics Pharmaceuticals, Inc. | Compositions and methods for inhibition of HIV-1 infection |
| US8546143B2 (en) | 2001-01-09 | 2013-10-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| US7060273B2 (en) * | 2001-04-06 | 2006-06-13 | Progenics Pharmaceuticals, Inc. | Methods for inhibiting HIV-1 infection |
| US7737124B2 (en) | 2001-09-13 | 2010-06-15 | California Institute Of Technology | Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell |
| ES2601141T3 (es) | 2001-09-13 | 2017-02-14 | California Institute Of Technology | Método para la expresión de moléculas de ARN pequeño dentro de una célula |
| US7122185B2 (en) * | 2002-02-22 | 2006-10-17 | Progenics Pharmaceuticals, Inc. | Anti-CCR5 antibody |
| AU2003281858A1 (en) * | 2002-07-26 | 2004-02-23 | Consejo Superior De Investigaciones Cientificas | Multifunctional genetic constructions having a high capacity to inhibit the expression of ccr5 on the cell surface |
| JP2006500017A (ja) * | 2002-07-31 | 2006-01-05 | シティ・オブ・ホープ | ＲＮＡ発現のためのアデノウイルスのＶＡ１ＰｏｌＩＩＩ発現システム |
| US8389244B2 (en) * | 2002-08-01 | 2013-03-05 | City Of Hope | Methods and kits for synthesis of siRNA expression cassettes |
| WO2004055198A2 (en) * | 2002-12-12 | 2004-07-01 | Chiron Corporation | Device and method for in-line blood testing using biochips |
| CA2548502A1 (en) | 2003-12-11 | 2005-06-30 | Yale University | Methods and compositions relating to ccr5 antagonist, ifn-.gamma. and il-13 induced inflammation |
| CA2616189C (en) * | 2005-07-22 | 2019-03-26 | Progenics Pharmaceuticals, Inc. | Methods for reducing viral load in hiv-1-infected patients |
| US7919583B2 (en) | 2005-08-08 | 2011-04-05 | Discovery Genomics, Inc. | Integration-site directed vector systems |
| US20090074766A1 (en) * | 2007-09-14 | 2009-03-19 | Ketas Thomas J | Methods of inhibiting HIV-2 infection |
| WO2010008562A2 (en) | 2008-07-16 | 2010-01-21 | Recombinetics | Methods and materials for producing transgenic animals |
| US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5496698A (en) * | 1992-08-26 | 1996-03-05 | Ribozyme Pharmaceuticals, Inc. | Method of isolating ribozyme targets |
| US5525468A (en) * | 1992-05-14 | 1996-06-11 | Ribozyme Pharmaceuticals, Inc. | Assay for Ribozyme target site |
| WO1997032019A2 (en) * | 1996-03-01 | 1997-09-04 | Euroscreen S.A. | C-c ckr-5, cc-chemikines receptor, derivatives thereof and their uses |
| EP0975749A2 (en) * | 1996-05-28 | 2000-02-02 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Cc chemokine receptor 5, antibodies thereto, transgenic animals |
| WO1998005798A1 (en) * | 1996-08-08 | 1998-02-12 | The Aaron Diamond Aids Research Center | Hiv coreceptor mutants |
| US5939538A (en) * | 1996-10-25 | 1999-08-17 | Immusol Incorporated | Methods and compositions for inhibiting HIV infection of cells by cleaving HIV co-receptor RNA |
| AU763325B2 (en) * | 1998-01-15 | 2003-07-17 | King's College London | Ribozymal nucleic acids cleaving CCR5 or CXCR4 |
-
1998
- 1998-03-11 US US09/038,741 patent/US6100087A/en not_active Expired - Lifetime
-
1999
- 1999-03-05 AT AT99911197T patent/ATE342969T1/de not_active IP Right Cessation
- 1999-03-05 EP EP99911197A patent/EP1062330B1/en not_active Expired - Lifetime
- 1999-03-05 DE DE69933653T patent/DE69933653T2/de not_active Expired - Lifetime
- 1999-03-05 WO PCT/US1999/005011 patent/WO1999046372A2/en active IP Right Grant
- 1999-03-05 CA CA002323109A patent/CA2323109A1/en not_active Abandoned
- 1999-03-05 JP JP2000535739A patent/JP4330797B2/ja not_active Expired - Lifetime
- 1999-03-05 AU AU29897/99A patent/AU2989799A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE69933653D1 (de) | 2006-11-30 |
| ATE342969T1 (de) | 2006-11-15 |
| EP1062330B1 (en) | 2006-10-18 |
| WO1999046372A3 (en) | 1999-11-04 |
| DE69933653T2 (de) | 2007-08-23 |
| EP1062330A2 (en) | 2000-12-27 |
| JP4330797B2 (ja) | 2009-09-16 |
| WO1999046372A2 (en) | 1999-09-16 |
| CA2323109A1 (en) | 1999-09-16 |
| US6100087A (en) | 2000-08-08 |
| JP2002505876A (ja) | 2002-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6100087A (en) | Ribozymes targeted to human CCR5 mRNA | |
| Wagner et al. | Potent and selective inhibition of gene expression by an antisense heptanucleotide | |
| Ojwang et al. | Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme. | |
| Beck et al. | Efficient hammerhead ribozyme-mediated cleavage of the structured heapatitis B virus encapsidation signal in vitro and in cell extracts, but not in intact cells | |
| US6034233A (en) | 2'-O-alkylated oligoribonucleotides and phosphorothioate analogs complementary to portions of the HIV genome | |
| US6057153A (en) | Stabilized external guide sequences | |
| US20020160393A1 (en) | Double-stranded RNA-mediated gene suppression | |
| Marschall et al. | Inhibition of gene expression with ribozymes | |
| US20090197336A1 (en) | Suppression of polymorphic alleles | |
| CA2086105A1 (en) | Method for treating leukemias | |
| AU763325B2 (en) | Ribozymal nucleic acids cleaving CCR5 or CXCR4 | |
| WO2000032765A9 (en) | Ribozyme therapy for the treatment and/or prevention of restenosis | |
| Rossi | Therapeutic applications of catalytic antisense RNAs (ribozymes) | |
| US6656731B1 (en) | Nucleic acid catalysts with endonuclease activity | |
| Bertrand et al. | Anti-HIV therapeutic hammerhead ribozymes: targeting strategies and optimization of intracellular function | |
| AU692208B2 (en) | Inhibitors and target molecule co-localization | |
| AU2002246742B2 (en) | Double-stranded RNA-mediated gene suppression | |
| WO1995022600A1 (en) | Ribozyme therapy for hepatitis b infection | |
| AU2004205192B2 (en) | Production of ssDNA in vivo | |
| KR20100083575A (ko) | ＴＥＬ-ＡＭＬ1 키메릭 ｍＲＮＡ를 특이적으로 절단하는 핵산 분자 | |
| Ganousis et al. | Improved accumulation and activity of ribozymes expressed from tRNA-based RNA polymerase III promoter | |
| WO1997008309A2 (en) | Ribozyme therapy for hepatitis b infections | |
| Roberts et al. | Efficient expression of ribozyme and reduction of stromelysin mRNA in cultured cells and tissue from rabbit knee via Adeno-associated Virus (AAV) | |
| Trang | M1 RNase P Ribozyme as a Novel Therapeutic Treatment for Human Herpesviruses | |
| WO1997008309A9 (en) | Ribozyme therapy for hepatitis b infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |